metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)
versus everolimus
	nivolumab alone
	CheckMate 025, 2015 N Engl J Med 2015;373:1803-13 Jpn. J. Clin. Oncol. 2019; 49:506-514 Jpn. J. Clin. Oncol. 2017; 47:639-646 Eur. Urol. 2017; 72:368-376 Eur. Urol. 2017; 72:962-971 Lancet Oncol. 2016; 17:994-1003 NCT01668784	RCT	metastatic/advanced RCC (mRCC) - 2nd line (L2)	nivolumab	everolimus	patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy	410 / 411	some concern	conclusif	demonstrated 27 % decrease in deaths (OS) (PE) demonstrated 5.0-fold increase in objective responses (ORR) (PE)